BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20208318)

  • 1. Translational research in pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2010 Mar; 11(2):124-7. PubMed ID: 20208318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The first-line treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Merl MY; Li J; Saif MW
    JOP; 2010 Mar; 11(2):148-50. PubMed ID: 20208324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palliative care from the beginning of treatment for advanced pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Lazenby JM; Saif MW
    JOP; 2010 Mar; 11(2):154-7. PubMed ID: 20208326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Bussom S; Saif MW
    JOP; 2010 Mar; 11(2):128-30. PubMed ID: 20208319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Richter J; Saif MW
    JOP; 2010 Mar; 11(2):139-43. PubMed ID: 20208322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Xu X; Strimpakos AS; Saif MW
    JOP; 2011 Jul; 12(4):325-9. PubMed ID: 21737888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Any second-line therapy for advanced pancreatic cancer? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Li J; Merl MY; Saif MW
    JOP; 2010 Mar; 11(2):151-3. PubMed ID: 20208325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Merika E; Syrigos KN; Saif MW
    JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in the treatment of locally advanced pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
    Triano LR; Chang BW; Saif MW
    JOP; 2009 Jul; 10(4):366-72. PubMed ID: 19581736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic cancer: updates on translational research and future applications.
    Sarris EG; Syrigos KN; Saif MW
    JOP; 2013 Mar; 14(2):145-8. PubMed ID: 23474558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraductal papillary mucinous neoplasia (IPMN). Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Bussom S; Saif MW
    JOP; 2010 Mar; 11(2):131-4. PubMed ID: 20208320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational research. New findings and potential future applications in pancreatic adenocarcinoma.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2012 Mar; 13(2):177-9. PubMed ID: 22406595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of pancreatic cancer.
    Eguia V; Gonda TA; Saif MW
    JOP; 2012 Mar; 13(2):131-4. PubMed ID: 22406583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
    Singh P; Srinivasan R; Wig JD
    Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
    El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
    Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA and pancreatic cancer: selection of chemotherapy.
    Kim R; Byer J; Saif MW
    JOP; 2012 Mar; 13(2):180-1. PubMed ID: 22406596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs in the treatment of pancreatic cancer.
    Mahalingam D; Kelly KR; Swords RT; Carew J; Nawrocki ST; Giles FJ
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):311-28. PubMed ID: 19466902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Richter J; Saif MW
    JOP; 2010 Mar; 11(2):144-7. PubMed ID: 20208323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Kang SP; Saif MW
    JOP; 2010 Jul; 11(4):334-5. PubMed ID: 20601806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations in improving detection of pancreatic adenocarcinoma.
    Mendieta Zerón H; García Flores JR; Romero Prieto ML
    Future Oncol; 2009 Jun; 5(5):657-68. PubMed ID: 19519205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.